# US 9,750,757 B2 · Methods of prevention or treatment for pathologic thrombosis or inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,757 B2
- Document ID: US9750757B2
- Status: Granted
- Kind: B2
- Application number: 15/032,790
- Filed: 2014-10-27
- Published: 2016-09-22
- Granted: 2017-09-05
- Earliest claimed: 2013-10-29
- Assignees: Thomas Jefferson University
- Applicants: Thomas Jefferson University
- Inventors: Paul F. Bray; Michael Holinstat
- Web page: https://patentgrep.com/patent/US9750757B2

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.

## Claims

### Claim 1

A method of inhibiting platelet activation, the method comprising contacting a platelet with a PC-TP inhibitor 2,4-dichloro-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenylcarbamoyl)-benzamide (LDN-193,188), or a pharmaceutically acceptable salt thereof, and wherein the PC-TP inhibitor inhibits PAR4 activation.

### Claim 2 (depends on 1)

The method of claim 1, wherein said contacting is in vitro.

### Claim 3 (depends on 1)

The method of claim 1, wherein said contacting is in vivo.

### Claim 4 (depends on 3)

The method of claim 3, wherein said in vivo contacting is in a subject in need of prevention or treatment for pathologic thrombosis, or treatment for a disorder treatable by a PAR4 inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein said subject is a mammal.

### Claim 6 (depends on 5)

The method of claim 5, wherein said mammal is a human.